ＦＲＯＮＴＥＯ was selected for Tokyo's support program for the growth of mid-sized companies, Next Edge Tokyo, and will expand the capabilities of its AI drug discovery support service and strengthen its research and development structure.
ＦＲＯＮＴＥＯ was selected for Next Edge Tokyo, Tokyo's support program for the growth of mid-sized companies. The program covers its AI drug discovery support service, Drug Discovery AI Factory, through which the company will expand its capabilities and strengthen its drug discovery-related research and development structure.
As part of the support, the company plans to use a subsidy of up to ¥100 million. In addition to exploring target molecules and indications, it will develop safety prediction and compound exploration capabilities and promote the automation of analysis.
The company will use its collaboration with Institute of Science Tokyo as a joint research center, recruit and develop specialized personnel at its own research facilities, and seek to expand collaboration with pharmaceutical companies and universities.